Attruby™

Drug - Attruby™ (acoramidis) [BridgeBio Pharma, Inc.]

July 2025

Therapeutic Area - ATTR-Cardiac Amyloidosis (ATTR-CM)

Initial approval criteria

Patient is at least 18 years old AND
Patient has a diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis confirmed by testing (e.g., stannous pyrophosphate [PYP] scanning, monoclonal antibody studies, biopsy, scintigraphy, genetic testing [TTR genotyping]) AND
Patient has New York Heart Association (NYHA) Functional Class I, II, or III Heart Failure AND
Patient has clinical manifestations of cardiomyopathy (e.g., dyspnea, fatigue, orthostatic hypotension, syncope, peripheral edema) AND
The prescriber is a specialist in the area of patient’s diagnosis (e.g., cardiologist, geneticist), or the prescriber has consulted with a specialist in the area of patient’s diagnosis AND
Patient will NOT be using Attruby in combination with an RNA-targeted therapy for ATTR amyloidosis [i.e., Amvuttra (vutrisiran), Onpattro (patisiran), Tegsedi (inotersen), Vyndaqel/Vyndamax (tafamadis), or Wainua (eplontersen)] AND
Patient does NOT have any FDA labeled contraindications to Attruby.

Patient has had clinical benefit with Attruby AND
Patient has New York Heart Association (NYHA) Functional Class I, II, or III Heart Failure AND
The prescriber is a specialist in the area of patient’s diagnosis (e.g., cardiologist, geneticist), or the prescriber has consulted with a specialist in the area of patient’s diagnosis AND
Patient will NOT be using Attruby in combination with an RNA-targeted therapy for ATTR amyloidosis [i.e., Amvuttra (vutrisiran), Onpattro (patisiran), Tegsedi (inotersen), Vyndaqel/Vyndamax (tafamadis), or Wainua (eplontersen)] AND
Patient does NOT have any FDA labeled contraindications to Attruby

Provider Call Center (844) 575-7887